Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Christine Dierks*, Jochen Seufert, Konrad Aumann, Juri Ruf, Claudius Klein, Selina Kiefer, Michael Rassner, Melanie Boerries, Andreas Zielke, Paul La Rosee, Philipp Tobias Meyer, Matthias Kroiss, Christian Weißenberger, Tilmann Schumacher, Patrick Metzger, Harald Weiss, Constantin Smaxwil, Katharina Laubner, Justus Duyster, Nikolas Von BubnoffCornelius Miething, Oliver Thomusch
Dive into the research topics of 'Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma'. Together they form a unique fingerprint.